Log In
BCIQ
Print this Print this
 

ManNAc, N-acetyl-D-mannosamine

  Manage Alerts
Collapse Summary General Information
Company New Zealand Pharmaceuticals Ltd.
DescriptionIntermediate in sialic acid biosynthesis
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationMuscular atrophy
Indication DetailsTreat hereditary inclusion body myopathy (HIBM)
Regulatory Designation U.S. - Orphan Drug (Treat hereditary inclusion body myopathy (HIBM))
PartnerEscala Therapeutics Inc.;
Fortress Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/17/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today